T-326 Inhaler
DeviceNo drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
NCT Number: NCT02563197
Study should show feasibility of the device for drug delivery into the lung independently of the severity of impaired lung function.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 1
Gauting, Bavaria, Germany
The aim of the study is to measure inspiratory profiles of patients with non-Cystic fibrosis bronchiectasis using the breath activated T-326 Inhaler.
The following parameters will be derived from the inspiratory profiles:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
Time frame: Visit 2 (1-14 days after screening visit 1)
Time frame: Visit 2 (1-14 days after screening visit 1)
Time frame: Visit 2 (1-14 days after screening visit 1)
Bayer
Industry
An Open, Multi-center Study to Measure Inhaled Flow Rates Generated by Non-CF Bronchiectasis Patients for the T-326 Inhaler
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05238675
Bronchial Diseases, Bronchiectasis
Peoria, Arizona, United States
View Trial DetailsNCT02804971
Bronchial Diseases, Bronchiectasis
Créteil, France
View Trial DetailsNCT05865886
Bronchial Diseases, Bronchiectasis
Denver, Colorado, United States
View Trial DetailsNCT07063290
Bronchial Diseases, Bronchiectasis
Hangzhou, Zhejiang, China
View Trial Details